AR027677A1 - Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer - Google Patents

Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer

Info

Publication number
AR027677A1
AR027677A1 ARP010101256A ARP010101256A AR027677A1 AR 027677 A1 AR027677 A1 AR 027677A1 AR P010101256 A ARP010101256 A AR P010101256A AR P010101256 A ARP010101256 A AR P010101256A AR 027677 A1 AR027677 A1 AR 027677A1
Authority
AR
Argentina
Prior art keywords
cancer
treatment
cyclofosphamide
camptotechine
pharmaceutical composition
Prior art date
Application number
ARP010101256A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR027677A1 publication Critical patent/AR027677A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen combinaciones terapéuticas que comprenden una cantidad efectiva de camptotecina (CPT-11) con una cantidad efectiva de un agente alquilantepara el tratamiento del cáncer.
ARP010101256A 2000-03-17 2001-03-16 Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer AR027677A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19000700P 2000-03-17 2000-03-17

Publications (1)

Publication Number Publication Date
AR027677A1 true AR027677A1 (es) 2003-04-09

Family

ID=22699678

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101256A AR027677A1 (es) 2000-03-17 2001-03-16 Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer

Country Status (6)

Country Link
US (1) US6548488B2 (es)
EP (1) EP1267873A2 (es)
JP (1) JP2003526659A (es)
AR (1) AR027677A1 (es)
AU (1) AU2001252235A1 (es)
WO (1) WO2001068066A2 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2581133A1 (en) * 2004-09-20 2006-03-30 British Columbia Cancer Agency Free or liposomal gemcitabine alone or in combination with free or liposomal idarubicin
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
US7671067B2 (en) 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
KR20080091829A (ko) * 2006-02-09 2008-10-14 엔존 파마슈티컬즈, 인코포레이티드 유방암, 대장암, 췌장암, 난소암 및 폐암 치료용 7―에틸―10―히드록시캄포테신의 다분지형 고분자 접합체
AU2008213576B2 (en) 2007-02-09 2013-01-17 Enzon Pharmaceuticals, Inc. Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
US4981968A (en) 1987-03-31 1991-01-01 Research Triangle Institute Synthesis of camptothecin and analogs thereof
CA1332413C (en) 1987-06-25 1994-10-11 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
JPH0615547B2 (ja) 1988-01-20 1994-03-02 株式会社ヤクルト本社 新規なカンプトテシン誘導体
DE69209969T2 (de) 1991-10-29 1996-09-12 Glaxo Wellcome Inc Wasserlösliche Camptothecinderivate
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US6504029B1 (en) 1995-04-10 2003-01-07 Daiichi Pharmaceutical Co., Ltd. Condensed-hexacyclic compounds and a process therefor
GB9510716D0 (en) 1995-05-26 1995-07-19 Pharmacia Spa Substituted camptothecin derivatives and process for their preparation
US5663177A (en) 1995-05-31 1997-09-02 Smithkline Beecham Corporation Water soluble camptothecin analogs
US5670500A (en) 1995-05-31 1997-09-23 Smithkline Beecham Corporation Water soluble camptothecin analogs
US6191119B1 (en) 1999-10-15 2001-02-20 Supergen, Inc. Combination therapy including 9-nitro-20(S)-camptothecin

Also Published As

Publication number Publication date
EP1267873A2 (en) 2003-01-02
WO2001068066A3 (en) 2002-06-20
US20010056082A1 (en) 2001-12-27
JP2003526659A (ja) 2003-09-09
WO2001068066A2 (en) 2001-09-20
US6548488B2 (en) 2003-04-15
AU2001252235A1 (en) 2001-09-24

Similar Documents

Publication Publication Date Title
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
PA8588601A1 (es) Administracion combinada de una indolinona junto a un agente quimioterapeutico para el tratamiento de enfermedades de proliferacion celular
AR026610A1 (es) Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
HN2001000244A (es) Inhibidores de espiropirimidin - 2, 4, 6 - triona metaloproteinasas.
UY27943A1 (es) Composiciones y mctodos para tratar el crncer usando inmunoconjugados de anticuerpo para cd44 citotnxicos y agentes quimioterapcuticos
BR0112054A (pt) Composição formadora de micelas, e métodos para a administração e a proteção de um agente terapêutico
AR029763A1 (es) Uso de una combinacion de una nsaid y un inhibidor de quinasa egfr para la manufactura de un medicamento para el tratamiento o inhibicion de polipos colonicos y cancer colorectal, composicion farmaceutica y medicamento
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
AR027355A1 (es) Acidos tiazolidincarboxilicos
AR023806A1 (es) Uso de una mezcla de peptidos para la manufactura de un agente terapeutico para la profilaxis y/o el tratamiento del cancer, las composicionesfarmaceuticas y vacunas que contienen dicha mezcla y los procedimientos de preparacion de dichas composiciones y vacunas
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
UY27208A1 (es) Una combinación que comprende combretastatina y agentes anticarcinógenos.
EE200200471A (et) Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
ES2188995T3 (es) Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales.
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
AR027677A1 (es) Una composicion farmaceutica terapeutica que comprende camptotecina y ciclofosfamida para el tratamiento del cancer
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
UY28461A1 (es) Composición nueva
GT200000194A (es) Quimioterapia de combinacion.

Legal Events

Date Code Title Description
FB Suspension of granting procedure